Stock DRIO DARIOHEALTH CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials DarioHealth Corp.

Equities

DRIO

US23725P2092

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.48 USD +0.68% Intraday chart for DarioHealth Corp. +27.59% -13.95%
Apr. 25 DarioHealth Corp. Publishes New Peer-Reviewed Study That Deepens the Body of Evidence That Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes CI
Apr. 18 DarioHealth Corp. Signs Two Employers for Cardiometabolic Suite with Integrated Glp-1 Solution CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14.67 116 215 109.9 46.81 43.92 - -
Enterprise Value (EV) 1 14.67 116 215 109.9 46.81 43.92 43.92 43.92
P/E ratio -0.82 x -3.56 x -3.19 x -1.69 x -0.89 x -0.87 x -1.05 x -2.03 x
Yield - - - - - - - -
Capitalization / Revenue 1.94 x 15.3 x 10.5 x 3.97 x 2.3 x 1.18 x 0.88 x 0.6 x
EV / Revenue 1.94 x 15.3 x 10.5 x 3.97 x 2.3 x 1.18 x 0.88 x 0.6 x
EV / EBITDA -0.96 x -6.23 x -4.6 x -3.1 x -1.49 x -1.46 x -4.49 x 3.1 x
EV / FCF - -6.49 x -4.08 x - - -1.91 x -7.52 x 8.93 x
FCF Yield - -15.4% -24.5% - - -52.4% -13.3% 11.2%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 2,236 8,114 16,576 25,679 27,215 29,676 - -
Reference price 2 6.560 14.29 12.97 4.280 1.720 1.480 1.480 1.480
Announcement Date 3/17/20 3/9/21 3/22/22 3/9/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7.559 7.576 20.51 27.66 20.35 37.33 49.7 73.66
EBITDA 1 -15.26 -18.61 -46.69 -35.5 -31.5 -30 -9.774 14.17
EBIT 1 -17.7 -29.9 -76.49 -56.81 -56.19 -60.23 -50.06 -
Operating Margin -234.22% -394.71% -372.9% -205.42% -276.09% -161.33% -100.72% -
Earnings before Tax (EBT) 1 -17.74 -29.44 -76.73 -62.19 -59.36 -65.73 -50.08 -
Net income 1 -20.89 -33.1 -78.77 -63.84 -63.51 -61.31 -42.34 -20.82
Net margin -276.37% -436.95% -383.98% -230.82% -312.06% -164.23% -85.19% -28.27%
EPS 2 -8.000 -4.010 -4.070 -2.540 -1.930 -1.707 -1.415 -0.7300
Free Cash Flow 1 - -17.85 -52.68 - - -23.03 -5.841 4.917
FCF margin - -235.67% -256.79% - - -61.7% -11.75% 6.68%
FCF Conversion (EBITDA) - - - - - - - 34.7%
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/17/20 3/9/21 3/22/22 3/9/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 5.629 6.028 8.059 6.183 6.605 6.809 7.066 6.152 3.518 3.616 6.759 9.424 10.16 10.85 13.28
EBITDA 1 -11.84 -14.99 -9.861 -11.21 -8.327 -6.005 -6.245 -8.634 -9.151 -6.156 -8.8 -8.594 -7.152 -5.456 -3.378
EBIT 1 -22.5 -21.66 -15.87 -17.36 -14.57 -9.01 -12.41 -14.02 -15.55 -14.22 -17.48 -17.1 -16.26 -14.87 -
Operating Margin -399.7% -359.41% -196.95% -280.69% -220.64% -132.32% -175.6% -227.89% -441.9% -393.11% -258.65% -181.43% -159.99% -136.99% -
Earnings before Tax (EBT) 1 -22.44 -21.55 -15.92 -18.03 -15.63 -12.61 -12.82 -16.58 -15.73 -14.22 -17.49 -17.1 -16.27 -14.87 -
Net income 1 -22.93 -22.07 -16.37 -18.46 -16.13 -12.88 -12.82 -18.28 -15.73 -15.51 -15.36 -15.61 -14.66 -13.36 -10.47
Net margin -407.39% -366.14% -203.09% -298.58% -244.15% -189.19% -181.5% -297.07% -447.19% -428.82% -227.3% -165.66% -144.26% -123.06% -78.81%
EPS 2 -1.180 -1.090 -0.7400 -0.7400 -0.6400 -0.5100 -0.4500 -0.5800 -0.4900 -0.4100 -0.5300 -0.5400 -0.5000 -0.4550 -0.3700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/15/21 3/22/22 5/12/22 8/15/22 11/14/22 3/9/23 5/11/23 8/10/23 11/2/23 3/28/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -17.9 -52.7 - - -23 -5.84 4.92
ROE (net income / shareholders' equity) - - -91.1% -57.2% - -43.5% -6.8% -
ROA (Net income/ Total Assets) - - -76.1% -43.1% - -24.2% -3.6% -
Assets 1 - - 103.6 148.2 - 253.4 1,176 -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - 0.12 0.26 0.44 - 0.73 0.84 0.97
Capex / Sales - 1.56% 1.27% 1.6% - 1.96% 1.69% 1.31%
Announcement Date 3/17/20 3/9/21 3/22/22 3/9/23 3/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for DarioHealth Corp.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.48 USD
Average target price
5.667 USD
Spread / Average Target
+282.88%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
DARIOHEALTH CORP. Stock DarioHealth Corp.
-13.95% 43.92M
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. DRIO Stock
  4. Financials DarioHealth Corp.